ASCIA advocates on behalf of ASCIA members to government and other organisations by lodging submissions which are listed below.

• ASCIA submission in response to the Senate Inquiry into Red Imported Fire Ants in Australia. Lodged 1 December 2023. This submission has been published submission on the committee's webpage at the following link https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Rural_and_Regional_Affairs_and_Transport/FireAnts. 
  ASCIA Submission Fire Ants Inquiry 2023-12-01118.29 KB

• Joint submission in response to draft National Safety and Quality Health Service Standards Guide for Ambulance Health Services from ASCIA, the National Allergy Council, and Allergy & Anaphylaxis Australia. Lodged 8 November 2023.

• ASCIA statement on clinical need to maintain supply of VIT for bees and wasps submitted to Pharmac NZ. Lodged  13 October 2023.

• ASCIA response to PBS post marketing investigation of the use of omalizumab in chronic spontaneous urticaria. Lodged 19 September 2023.

• ASCIA submission to ACECQA for approval of ASCIA anaphylaxis e-training for children's education and care. Lodged 1 September 2023. ACECQA approval has been confirmed until  October 2026. Read more here 

• ASCIA letter to the Hon Mark Butler MP, Minister for Health and Ageing, Commonwealth of Australia
  regarding implementation of newborn screening. Submitted 15 August 2023
  
  ASCIA letter to Minister Butler re Newborn Screening 2023-08-15 151.60 KB

• ASCIA submission in response to the Food Standards Australia New Zealand (FSANZ) call for submissions on Proposal P1028 – Infant Formula.  Submission lodged 13 July 2023.
  
  ASCIA FSANZ P1028 Response July 2023258.66 KB

• ASCIA submissions on 23 May 2023 in support of two products that are relevant to allergy and immunology, which are on the July 2023 PBAC meeting agenda.

ASCIA letter PBAC Avacopan 2023 05 2366.18 KB

 ASCIA letter PBAC Dupilumab 2023 05 2367.24 KB

• ASCIA letter to the Australian Government Department of Health, to provide information to address the Medical Treatment Overseas Program (MTOP) eligibility criteria for thymic transplant, submitted in May 2023.

• ASCIA has submitted two letters in support of applications for  Medical Research Future Fund (MRFF) research grants, in February and May 2023.

• ASCIA has submitted two joint letters to the federal Health Minister, the Hon Mark Butler MP, with the National Allergy Council and Allergy & Anaphylaxis Australia regarding the feasibility of pricing for PBS listed products -  venom immunotherapy (May 2023) and medical nutrition products for cow’s milk allergy (April 2023).

• ASCIA has lodged four submissions on 20 January 2023 in support of applications for new or updated PBS listings of products that are relevant to allergy and immunology, which are on the March 2023 PBAC meeting agenda, as listed on the ASCIA website www.allergy.org.au/about-ascia/info-updates/pbac-meeting-march-2023
  
  ASCIA letter PBAC ELECARE LCP 2023-01-20117.39 KB
  
  ASCIA letter PBAC EoE JORVEZA 2023-01-2066.86 KB
  
  ASCIA letter PBAC SHINGRIX 2023-01-2067.84 KB
  
  ASCIA letter PBAC SLE ANIFROLUMAB 2023-01-2066.53 KB  

ASCIA advocates on behalf of ASCIA members to government and other organisations by lodging submissions which are listed below.

• ASCIA letter to Medical Services Advisory Committee (MSAC) in support for the Human Genetics Society of Australasia (HGSA) application for services provided by genetic counsellors, submitted on 7 October 2022.
  ASCIA supports HGSA MSAC application 20221007

• ASCIA letter to PBAC supporting the PBS listing of PBS Nucala® (mepolizumab) for treatment of nasal polyps in chronic rhinosinusitis, submitted on 20 September 2022.
  ASCIA letter PBAC Nucala 2022092069.78 KB Nucala® (mepolizumab) is now subsidised by the Pharmaceutical Benefits Scheme (PBS) from 1 April 2023 as an add-on treatment for adult patients (18 years and above) with chronic rhinosinusitis with nasal polyps (CRSwNP) that is severe, eosinophilic and recurrent post-surgery.. Read more here

• ASCIA feedback to RACP on the draft Australian Government’s National Medicine Policy (NMP), submitted on 19 September 2022.
  ASCIA feedback AU Govt National Medicine Policy 20220919154.14 KB

• ASCIA statement on the high clinical need to maintain supply of venom immunotherapy (VIT) on the PBS, submitted on 15 September 2022.
  ASCIA letter PBAC VIT 20220915120.76 KB

• Joint letter to the federal Health Minister, the Hon Mark Butler MP, regarding pricing of medical nutrition products for cow’s milk allergy has been sent on behalf of ASCIA, Allergy & Anaphylaxis Australia and the National Allergy Strategy, submitted on 28 July 2022.

• Letters from ASCIA supporting research project appications to the Medical Research Future Fund (MRFF) have been submitted on 16 February, 3 March, 16 May, 24 June and 1 July 2022.

• ASCIA letter to the Australian Government Department of Health, to provide information to address the Medical Treatment Overseas Program (MTOP) eligibility criteria about a SCID-ADA patient, in response to a request sent to ASCIA on 8 July 2022. Lodged 20 July 2022. 

• ASCIA letter to the Coroners Court of Victoria in response to the Coroner’s recommendations regarding the death of Peta Hickey. Lodged 13 April 2022.
  ASCIA letter Coroners Court Victoria 2022-04-13 

• ASCIA submitted responses to a survey on the Consultation Draft - National Medicines Policy. Lodged 2 March 2022. 

• ASCIA contributed to the RACP’s Pre-Budget Submission 2022-2023 titled Delivering a Future-Focused Health System for Equitable Care and Healthier Communities Lodged January 2022.

• Letter from ASCIA in support of the application to the PBAC for PBS listing of Dupixent® (dupilumab) for treatment of severe atopic dermatitis (eczema) in children aged 6-11 years. Lodged 13 January 2022.
  ASCIA letter PBAC Dupilumab 2022 01 1352.73 KB

• ASCIA letter to the Australian Government Department of Health, to provide information to address the Medical Treatment Overseas Program (MTOP) eligibility criteria about a patient with DiGeorge Syndrome and Severe Combined Immune Deficiency (SCID), in response to a request sent to ASCIA on 4 January 2022. Lodged 12 January 2022. 

ASCIA advocates on behalf of ASCIA members to government and other organisations by lodging submissions which are listed below.

• ASCIA response to FSANZ Proposal P1028 – Infant Formula Consultation Paper 3 - Regulatory framework and definitions. Lodged 20 October 2021. 
  ASCIA FSANZ Infant formula response 20 October 2021950.61 KB

• ASCIA responded to a request for information from the Australian Technical Advisory Group on Immunisation (ATAGI) on 24 September 2021. On 8 October 2021 ATAGI  released a statement, prepared in consultation with ASCIA, on the use of a third primary ‘booster’ dose of COVID-19 vaccine in severely immunocompromised people, including people with primary immunodeficiencies.  
  https://www.health.gov.au/news/atagi-statement-on-the-use-of-a-3rd-primary-dose-of-covid-19-vaccine-in-individuals-who-are-severely-immunocompromised

• ASCIA letter to PBAC in support of the Jorveza® (Budesonide 0.5 and 1mg) application for treatment of eosinophilic oesophagitis (EoE). Lodged 22 September 2021. 
  ASCIA letter PBAC EoE Budesonide 2021-09-2253.15 KB

• ASCIA response to National Blood Authority (NBA) call for public comments on the draft Acute Transfusion Reaction Guidelines. Lodged online 2 July 2021.

• ASCIA letter to the Coroners Court of Victoria, in response to the Coroner’s Findings into the death of Catherin D’Rozario on 25 August 2019. Lodged 22 June 2021.
  ASCIA letter to the Coroners Court of Victoria 2021-06-22156.36 KB

• ASCIA submission to PBAC regarding adrenaline (epinephrine) autoinjector prescriptions. Lodged 7 April 2021.
  ASCIA letter PBAC re Adrenaline 2021-04-07111.28 KB

• ASCIA submission to TGA regarding Anapen adrenaline autoinjectors. Lodged 23 February 2021. 
  ASCIA letter TGA Anapen 2021-02-2362.19 KB

• ASCIA submission to PBAC regarding the Jorveza® (Budesonide 1mg) application for adults with eosinophilic oesophagitis (EoE). Lodged 10 February 2021.
  ASCIA_letter_PBAC_EoE_Budesonide_2021-02-10106.76 KB 

ASCIA advocates on behalf of ASCIA members to government and other organisations by lodging submissions which are listed below.

• ASCIA submission to the Australian Commission on Safety and Quality in Health Care on the draft Acute Anaphylaxis Clinical Care Standard. Lodged 13 December 2020.
  ASCIA Feedback Anaphylaxis Clinical Std 2020-12-13137.58 KB 

• ASCIA submission to the House of Representatives Standing Committee for Health, Aged Care and Sport Parliamentary Inquiry into new drugs and novel medical technologies. Lodged 3 November 2020 
  ASCIA_Submission_Parliamentary_Inquiry_2020.pdf173.17 KB  Note: This is also listed as Submission 147 on https://www.aph.gov.au/Parliamentary_Business/Committees/House/Health_Aged_Care_and_Sport/Newdrugs/Submissions

• ASCIA Immunodeficiency Strategy for Australia and New Zealand. Completed November 2020 and lodged as an attached to the ASCIA submission to the Parliamentary Inquiry 3 November 2020. 

  www.nationalimmunodeficiencystrategy.org.au/

• ASCIA response to Medical Research Future Fund consultation to inform the third Australian Medical Research and Innovation Priorities 2020-2022. Lodged 7 October 2020.
  ASCIA MRFF consultation response 2020-10-0712.09 KB

• ASCIA response to dupilumab (Dupixent®) application for severe uncontrolled asthma (included in the November 2020 PBAC meeting agenda). Lodged 21 September 2020.
  ASCIA letter PBAC re Dupilumab 2020-09-2147.86 KB

• ASCIA response to Anapen adrenaline (epinephrine) autoinjector application (included in the November 2020 PBAC meeting agenda). Lodged 17 September 2020. 
  ASCIA letter PBAC re Anapen 2020-09-1764.48 KB

• ASCIA submissions to Medical Services Advisory Committee (MSAC) Immunoglobulin Review Consultations 1591 and 1592. Lodged 10 September 2020. 
  MSAC – 1591 – Secondary hypogammaglobulinaemia unrelated to haematological malignancies, or post-haematopoietic stem cell transplantation (HSCT)200.69 KB 
  MSAC – 1592 – Primary Immunodeficiency diseases (PID) with antibody deficiency203.92 KB 

• ASCIA response to FSANZ Call for Submissions on Application A1175 – Rapeseed Protein Isolate as a Novel Food. Lodged 4 September 2020.  ASCIA letter FSANZ 2020-09-0493.87 KB

• ASCIA pre-budget submission. Lodged 24 August. This is an amended version of the submission lodged in January 2020. ASCIA Pre-Budget Submission 2020-2021 2020-08-24 400.83 KB

• ASCIA letter to the Minister for Health (Hon Greg Hunt MP) regarding ASCIA feedback on recommendations in the Allergies and Anaphylaxis Inquiry Report. Submitted 14 July 2020.
  ASCIA Letter re Feedback on Recommendations in the Allergies and Anaphylaxis Inquiry Report155.79 KB
  Feedback on Recommendations in the Report from the Allergies and Anaphylaxis Parliamentary Inquiry230.05 KB

• Joint letter from ASCIA, National Allergy Strategy, A&AA and CFAR to the Minister for Health (Hon Greg Hunt MP), in response to Recommendation 1 in the Report on the Parliamentay Inquiry into Allergies and Anaphylaxis. Submitted 30 June 2020. Joint letter to Minister Hunt 30-06-20100.27 KB

• ASCIA letter to the Minister for Health (Hon Greg Hunt MP) in response to the Report on the Parliamentay Inquiry into Allergies and Anaphylaxis Walking the allergy tightrope - Addressing the rise of allergies and anaphylaxis in Australia tabled on 15 June 2020 in the Parliament of the Commonwealth of Australia.  Submitted 19 June 2020. 
  ASCIA Letter Hon Greg Hunt 2020-06-19162.99 KB

• ASCIA letter to the Drug Utilisation Sub Committee (DUSC) of the PBAC regarding a confidential report on the use of omalizumab for the treatment of chronic spontaneous urticaria (CSU). Submitted 27 May 2020.  ASCIA letter DUSC PBAC re Omalizumab 20200527137.47 KB

• ASCIA letter to the Minister for Health (Hon Greg Hunt MP) and Chief Medical Officer (Professor Brendan Murphy), regarding the potential of immune blockers in treatment of COVID-19. Submitted 5 May 2020. A response was received on 10 June 2020. As of  August 2021 there are now shortages in Australia of Tociluzumab, an immune blocker which is being used internationally to treat COVID-19.
  ASCIA letter AU Govt re COVID19 Treatments 20200505 146.09 KB 
  IL-6_as_a_marker_of_outcome_in_COVID-19160.65 KB 
  Siltuximab_COVID-19_Italy531.28 KB 
  Tociluzumab_COVID-19_China1.64 MB

• ASCIA letter to PBAC regarding concerns about revised PBS listings for antibiotics and patients with immunodeficiencies. Submitted 27 April 2020.  ASCIA letter PBAC Immunodeficiencies Antibiotics 2020-04-2786.61 KB  Changes were made on 1 May 2020 to allow patients who require prolonged oral antibiotic therapy to access an increased maximum quantity and/or repeat(s), as described in Revised PBS listings for Antibiotic use

• ASCIA letter to PBAC regarding access to adrenaline (epinephrine) auto-injectors on the PBS. Submitted 24 April 2020. ASCIA letter PBAC Anaphylaxis Adrenaline 20200424131.90 KB

• Joint letter from A&AA, ASCIA, National Allergy Strategy and CFAR to the Ministerial Forum on Food Regulation and FSANZ P1053. Submitted 30 April 2020. Ministerial Forum P1053 Final 300420753.65 KB  FSANZ has responded that they will continue to consider allergen management within the scope of the chapter 3 review as the project progresses.

• ASCIA letter to the Minister for Health (Hon Greg Hunt MP), regarding telehealth changes. Submitted 7 April 2020. 
  ASCIA Letter Hon Greg Hunt 20200407137.54 KB Changes to telehealth have since been made, effective 20 April 2020. www.allergy.org.au/members/covid-19#cd4

• ASCIA letter to PBAC regarding dupilumab submission for atopic dermatitis. Submitted 2 March 2020. 
  ASCIA letter PBAC Dupilumab 2020030275.35 KB  Dupilumab has been recommended by the PBAC for PBS listing. For details refer to the announcement here.

• ASCIA submission to FSANZ  Plain English Labelling (PEAL) proposal P1044. Submitted 27 February 2020. 
  ASCIA FSANZ P1044 Submission 2020 02 27160.82 KB

• ASCIA pre-budget 2020-2021 submission. Submitted 10 January 2020. 
  ASCIA Pre-Budget Submission 2020-2021808.7 KB